Read more

June 15, 2023
1 min watch
Save

VIDEO: ADAURA results ‘practice changing’ for lung cancer

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

CHICAGO — Healio spoke with Karen L. Reckamp, MD, on updated findings from the ADAURA trial presented at ASCO Annual Meeting.

“The biggest practice-changing presentation was from the ADAURA trial, which is adjuvant osimertinib [(Tagrisso, AstraZeneca)] versus standard-of-care for patients who have EGFR-mutated non-small cell lung cancer status post-resection, stage IB through IIIA,” Reckamp, professor in medicine and director of the division of medical oncology at Cedars-Sinai Medical Center, said. “This was presented back in 2020 with improvement in disease-free survival, and this year the overall survival was presented and showed a significant improvement in overall survival in patients who had resected EGFR NSCLC.”

She said researchers observed the same benefit regardless of whether or not patients had received chemotherapy before receiving 3 years of osimertinib.

“This is clearly practice-changing and improved the overall survival rate for these patients who received osimertinib as adjuvant therapy,” Reckamp said.